Summary
Only the boxed warning/all-cause mortality-related claim set is supported by the provided label excerpts. Many other listed statements (indications, contraindications, pregnancy/breastfeeding, specific adverse reaction rates, and drug interaction/absorption claims) are not supported or verifiable against the supplied prescribing information, which does not include those sections.
Category Scores
Accurate Statements
TYGACIL should be reserved for use in situations when alternative treatments are not suitable due to an observed increase in all-cause mortality vs comparator, with an adjusted risk difference of 0.6% (95% CI 0.1, 1.2), and the cause has not been established.
BOX (Warning: All-Cause Mortality); 5.1 (All-Cause Mortality); 6.1 (Clinical Trials Experience)
Unsupported Statements
Tigecycline injection is used to treat severe infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and intra-abdominal infections.
No Indications and Usage content for these claims was provided in the supplied label excerpts.
Allergic reactions (hives, itching, difficulty breathing) may occur in 1-3% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Nausea and vomiting may occur in 10-20% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Diarrhea may occur in 5-10% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Diarrhea can be severe in some cases.
Severity statements for diarrhea were not provided in the supplied label excerpts.
Elevated liver enzymes may occur in 1-2% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Elevated liver enzymes can be a sign of liver damage.
This interpretive linkage is not present in the supplied label excerpts.
Headache may occur in 5-10% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Fatigue may occur in 2-5% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Thrombocytopenia (decrease in platelet count) may occur in 1-2% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Thrombocytopenia can increase the risk of bleeding.
Mechanistic/clinical consequence statement not supported by the supplied label excerpts.
Neutropenia (decrease in white blood cell count) may occur in 1-2% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Neutropenia can increase the risk of infection.
Mechanistic/clinical consequence statement not supported by the supplied label excerpts.
Cardiac arrhythmias (abnormal heart rhythms) may occur in 1-2% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Cardiac arrhythmias can be life-threatening.
Severity of cardiac arrhythmias not supported by the supplied label excerpts.
Seizures may occur in 1-2% of patients receiving tigecycline injection.
No adverse reaction incidence data were provided in the supplied label excerpts.
Seizures can be severe in some cases.
Severity statements for seizures not supported by the supplied label excerpts.
Antacids can reduce the absorption of tigecycline injection, making it less effective.
No drug-interaction/administration guidance was provided in the supplied label excerpts.
Histamine-2 (H2) receptors can reduce the absorption of tigecycline injection, making it less effective.
No drug-interaction/administration guidance was provided in the supplied label excerpts.
Tigecycline injection can increase the risk of bleeding in patients taking warfarin.
No drug-interaction information was provided in the supplied label excerpts.
Tigecycline injection is contraindicated in patients with a history of severe allergic reactions to tigecycline.
No contraindications section text was provided in the supplied label excerpts.
The effects of tigecycline injection on fetal development are unknown.
No pregnancy subsection/label text was provided in the supplied label excerpts.
The effects of tigecycline injection on breastfeeding are unknown.
No lactation/breastfeeding subsection/label text was provided in the supplied label excerpts.
Tigecycline injection is contraindicated in pregnancy.
No contraindication/pregnancy content was provided in the supplied label excerpts.
Tigecycline injection is contraindicated in breastfeeding.
No contraindication/lactation content was provided in the supplied label excerpts.
Patients with liver disease should be monitored closely because tigecycline injection can cause hepatotoxicity.
No warnings/precautions or hepatotoxicity monitoring guidance was provided in the supplied label excerpts.
Patients with kidney disease should be monitored closely because tigecycline injection can accumulate in the body and cause toxicity.
No warnings/precautions or accumulation/toxicity guidance was provided in the supplied label excerpts.
Contradictions
Important Omissions
The provided list does not mention or accurately reproduce key limitations of use regarding diabetic foot infections and hospital-acquired/ventilator-associated pneumonia (including higher mortality/decreased efficacy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several non-verified safety and contraindication statements are included (e.g., pregnancy/breastfeeding contraindications, bleeding risk with warfarin, hepatotoxicity/nephrotoxicity monitoring), but the supplied label excerpts do not provide the necessary support; additionally, limitations of use from the label were omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most listed claims are not supported by the provided prescribing-information excerpts (beyond the all-cause mortality/boxed warning content). Contraindications, population statements, adverse reaction incidence, and drug interaction/absorption claims cannot be verified against the supplied label text.
Suggested Improvement
Restrict statements to sections actually provided (BOX, 5.1, 6.1, and 5.2/1.4 excerpts). If other claims are needed, provide the corresponding FDA label sections (Indications and Usage, Contraindications, Warnings and Precautions, Drug Interactions, Adverse Reactions, and Use in Specific Populations) for verification.